Alzheon | Preserving future memories2019-03-19T16:21:21-04:00

A targeted approach to Alzheimer’s disease

Alzheon is developing ALZ-801, one of the few oral drug candidates in advanced stages of clinical testing in Alzheimer’s disease (AD). ALZ-801 is well-tolerated and has the potential to slow the course of the disease in patients with Alzheimer’s.

ALZ-801, an improved prodrug formulation, builds upon a large dataset in Alzheimer’s patients treated with the active molecule, tramiprosate.  Using a targeted approach, we are focusing on APOE4/4 homozygous patients with early to mild Alzheimer’s disease.

About ALZ-801

Alzheimer’s Program with Roadmap to Value Creation

Clinical Dataset Drives Strategy, Defines Population & Differentiates Lead Product

ALZ-801 Alzheimers

Projected Readout of Alzheimer’s Late-Stage Trials

ALZ-801 Potentially One of the First Approved Disease Modifying Drugs

Alzheimer's late stage trials

Source:  Study designs and timelines are based on ClinicalTrials.gov and information disclosed by competitors

Press Releases